All In Biotech

Drug Trial Radar · NCT05597735

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease

A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease

Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Mar 3, 2023

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
University Hospital, Geneva; Oswaldo Cruz Foundation; Fundacion Huesped, Buenos Aires, Argentina
First posted
Oct 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall purpose of this study is to evaluate whether tecovirimat is an efficient and safe antiviral in the treatment of monkeypox in adults and adolescents (14 years old and older). The primary objective is to evaluate the clinical efficacy, as assessed by time to all visible lesion(s) resolution, of tecovirimat treatment + Standard of Care (SOC) compared to placebo + SOC for patients with monkeypox. The secondary objective is to evaluate the clinical efficacy, as assessed by mortality, hospitalization, complications, duration of symptoms and virological shedding, and the safety of tecovirimat treatment + SOC compared to placebo + SOC in patients with monkeypox.

Conditions

  • Monkeypox
  • Mpox

Interventions

  • TecovirimatDrug

    The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis. The international recommended doses will be followed: * 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days. * 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.

  • PlaceboDrug

    The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to all visible lesion(s) resolutionTime frame: 28 days

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Fundación Huésped

    Buenos Aires, Argentina

  • Faculty of Medicine, Federal University of Minas Gerais

    Belo Horizonte, Brazil

  • Evandro Chagas National Institute of Infectious Diseases-Oswaldo Cruz Foundation-FIOCRUZ

    Rio de Janeiro, Brazil

  • Federal Hospital for State Employees

    Rio de Janeiro, Brazil

  • Nova Iguaçu General Hospital

    Rio de Janeiro, Brazil

  • University Hospital Prof. Edgard Santos

    Salvador, Brazil

  • Emílio Ribas Institute of Infectious Diseases

    São Paulo, Brazil

  • STD/AIDS Reference and Training Center

    São Paulo, Brazil

  • Hôpitaux Universitaires de Genève

    Geneva, Canton of Geneva, Switzerland

  • Pr Alexandra Calmy

    Geneva, Canton of Geneva, Switzerland

  • CHUV

    Lausanne, Canton of Vaud, Switzerland

  • Zürich checkpoint

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.